Sorafenib-Mediated Targeting of the AAA+ ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death

Ping Yi(Hangzhou Normal University), Éric Chevet(Inserm), Arisa Higa(Université de Bordeaux), Esther Marza(Inserm), Saı̈d Taouji(Mayo Clinic), Paulette Bioulac‐Sage(Université de Bordeaux), Brigitte Le Bail, Jean Rosenbaum(Inserm), Mariana G. Bexiga(Inserm), Claire Castain(Centre Hospitalier Universitaire de Bordeaux), Jeremy C. Simpson(University College Dublin), Jean‐Frédéric Blanc, Charles Balabaud(Inserm), Daniela Arma(Inserm)
Molecular Cancer Therapeutics
October 6, 2012
10.1158/1535-7163.mct-12-0516
Cited by 67

Related Papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
Endoplasmic Reticulum-Mediated Phagocytosis Is a Mechanism of Entry into Macrophages
|Cell|2002|678
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
|Journal of Clinical Oncology|2013|596
The role of hepatic resection in the treatment of hepatocellular cancer
|Hepatology|2015|418